BioElectronics Corporation

Equities

BIEL

US09062H1086

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 03:39:05 2024-04-26 pm EDT			5-day change	1st Jan Change
0.00015 ^USD	-25.00%		+100.00%	0.00%

Mar. 25	BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis Study	CI
Feb. 23	Bioelectronics Corporation Announces the Publication of Pilot Study Results	CI

Bioelectronics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020

August 10, 2020 at 09:25 pm EDT

BioElectronics Corporation announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was USD 118,092 compared to USD 141,103 a year ago. Operating loss was USD 367,604 compared to USD 319,509 a year ago. Net loss was USD 634,794 compared to USD 562,958 a year ago. Basic loss per share was USD 0.00003 compared to USD 0.00003 a year ago.

Latest news about BioElectronics Corporation

BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis Study	Mar. 25	CI
Bioelectronics Corporation Announces the Publication of Pilot Study Results	Feb. 23	CI
BioElectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-06	CI
BioElectronics Corporation Enters into a Distribution Agreement for RecoveryRx in Spain with Prim Group	22-04-06	CI
BioElectronics’ RecoveryRx Pain Relief Device Receives Clearance from Cofepris, Launching Distribution in Mexico	22-03-30	CI
BioElectronics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	22-02-15	CI
BioElectronics Corporation Reports Revenue Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-16	CI
BioElectronics Corporation Reports Revenue Results for the Second Quarter and Six Months Ended June 30, 2021	21-08-30	CI
BioElectronics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-18	CI
BioElectronics Corporation Reports Revenue Results for the First Quarter of 2021	21-04-19	CI
Bioelectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-12	CI
BioElectronics Corporation Reports Revenue Results for the Fourth Quarter of 2020	21-01-19	CI
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market	20-12-15	CI
BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy Advantage	20-11-06	CI
Bioelectronics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-08-10	CI
BioElectronics Corporation Announces Board Changes	20-06-15	CI
BioElectronics Corporation Announces U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain	20-02-03	CI
BioElectronics Announces New Management Team	19-11-15	CI
BioElectronics Corporation Announces Demise of Andrew J. Whelan, Founder and CEO	19-10-07	CI
BioElectronics Files FDA 510(k) Application for Musculoskeletal Pain Complaints	19-08-20	CI
Bioelectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-08-01	CI
BioElectronics Corporation Announces FDA Market Clearance for Its Non-Opioid Postoperative Pain Therapy	19-07-01	CI
Bioelectronics Corporation Responds to FDA’s 510(K) Additional Information Requests for Musculoskeletal Pain Relief and Postoperative Pain Applications	19-04-23	CI
BioElectronics Corporation Announces Back Pain Clinical Study with Leading Australian Pain Center	19-03-08	CI
BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain	19-02-12	CI

Chart BioElectronics Corporation

Duration

Period

More charts

Company Profile

BioElectronics Corporation is an electroceutical company. The Company develops wearables, neuromodulation devices to mitigate neurological diseases. Its pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. Its product line includes ActiPatch Musculoskeletal Pain Therapy, and RecoveryRx Post-operative and Chronic Wounds Therapy, which are sold by or on the order of medical professionals. Its flagship product, the ActiPatch Musculoskeletal Pain Therapy, is developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours of on/off therapy. The Company is also focused on international customers to expand its distributions and sales. The neuromodulation basis of PSWT presents significant opportunities for it to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIOELECTRONICS CORPORATION	0.00%	3.71M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology